164 related articles for article (PubMed ID: 2576130)
1. Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin.
Chungi VS; Dittert LW; Shargel L
Pharm Res; 1989 Dec; 6(12):1067-72. PubMed ID: 2576130
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
Klotz U
Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid.
Jung YJ; Lee JS; Kim YM
J Pharm Sci; 2000 May; 89(5):594-602. PubMed ID: 10756325
[TBL] [Abstract][Full Text] [Related]
4. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
[TBL] [Abstract][Full Text] [Related]
5. Cholestyramine-induced inhibition of salicylazosulfapyridine (sulfasalazine) metabolism by rat intestinal microflora.
Pieniaszek HJ; Bates TR
J Pharmacol Exp Ther; 1976 Jul; 198(1):240-5. PubMed ID: 6792
[TBL] [Abstract][Full Text] [Related]
6. Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin).
van Hees PA; Tuinte JH; van Rossum JM; van Tongeren JH
Gut; 1979 Apr; 20(4):300-4. PubMed ID: 36332
[TBL] [Abstract][Full Text] [Related]
7. Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats.
Shafii A; Chowdhury JR; Das KM
Am J Gastroenterol; 1982 May; 77(5):297-9. PubMed ID: 6123257
[TBL] [Abstract][Full Text] [Related]
8. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
Awni WM; Braeckman RA; Locke CS; Dubé LM; Granneman GR
Clin Pharmacokinet; 1995; 29 Suppl 2():98-104. PubMed ID: 8620678
[TBL] [Abstract][Full Text] [Related]
9. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
10. Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid.
Ambrosius Christensen L; Rasmussen SN; Hansen SH; Bondesen S; Hvidberg EF
Acta Obstet Gynecol Scand; 1987; 66(5):433-5. PubMed ID: 2892343
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of antibody secretion by 5-aminosalicylic acid.
MacDermott RP; Schloemann SR; Bertovich MJ; Nash GS; Peters M; Stenson WF
Gastroenterology; 1989 Feb; 96(2 Pt 1):442-8. PubMed ID: 2562949
[TBL] [Abstract][Full Text] [Related]
12. Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers.
Tokui K; Asai Y; Arakawa T; Matsumoto T; Nabeshima T
Biol Pharm Bull; 2002 Feb; 25(2):264-7. PubMed ID: 11853180
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine.
Das KM
Postgrad Med; 1983 Dec; 74(6):141-8, 150-1. PubMed ID: 6139795
[TBL] [Abstract][Full Text] [Related]
14. A simple and rapid liquid chromatographic method for the determination of major metabolites of sulfasalazine in biological fluids.
Chungi VS; Rekhi GS; Shargel L
J Pharm Sci; 1989 Mar; 78(3):235-8. PubMed ID: 2566674
[TBL] [Abstract][Full Text] [Related]
15. Role of the intestinal flora in the acetylation of sulfasalazine metabolites.
Dull BJ; Salata K; Goldman P
Biochem Pharmacol; 1987 Nov; 36(21):3772-4. PubMed ID: 2890356
[No Abstract] [Full Text] [Related]
16. Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs.
Takaya T; Sawada K; Suzuki H; Funaoka A; Matsuda K; Takada K
J Drug Target; 1997; 4(5):271-6. PubMed ID: 9169983
[TBL] [Abstract][Full Text] [Related]
17. Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease.
van Hogezand RA; van Hees PA; Zwanenburg B; van Rossum JM; van Tongeren JH
Gastroenterology; 1985 Mar; 88(3):717-22. PubMed ID: 2857146
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
Klotz U; Maier K; Fischer C; Heinkel K
N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
[TBL] [Abstract][Full Text] [Related]
19. Sulfasalazine and 5-aminosalicylic acid inhibit contractile leukotriene formation.
Nielsen ST; Beninati L; Buonato CB
Scand J Gastroenterol; 1988 Apr; 23(3):272-6. PubMed ID: 2898806
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of neutrophil degranulation and superoxide production by sulfasalazine. Comparison with 5-aminosalicylic acid, sulfapyridine and olsalazine.
Neal TM; Winterbourn CC; Vissers MC
Biochem Pharmacol; 1987 Sep; 36(17):2765-8. PubMed ID: 2888463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
